

Marzia Capelletti

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/45866/marzia-capelletti-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

65

papers

9,754

citations

35

h-index

66

g-index

66

ext. papers

11,181

ext. citations

12

avg, IF

5.04

L-index

#	Paper	IF	Citations
65	Synergism between CAR-T Cells and a Personalized Tumor Vaccine in Hematological Malignances. <i>Blood</i> , 2021 , 138, 737-737	2.2	
64	Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations. <i>Molecular Oncology</i> , 2021 , 15, 27-42	7.9	6
63	Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. <i>Haematologica</i> , 2021 , 106, 1330-1342	6.6	4
62	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. <i>Nature Communications</i> , 2020 , 11, 2996	17.4	34
61	Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. <i>Nature Cancer</i> , 2020 , 1, 493-506	15.4	73
60	Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma. <i>Leukemia</i> , 2019 , 33, 266-270	10.7	8
59	CD155-Tigit Pathway Modulation in Dendritic Cell/Acute Myeloid Leukemia Fusion Vaccine Model. <i>Blood</i> , 2019 , 134, 1386-1386	2.2	2
58	Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma. <i>Blood</i> , 2019 , 134, 392-392	2.2	2
57	T Cells Educated By DC/AML Fusions in the Context of 4-1BB Costimulation As a Potent Strategy for Adoptive Cellular Therapy. <i>Blood</i> , 2019 , 134, 2673-2673	2.2	1
56	Transcriptome Sequencing Demonstrates Unique Signature Associated with Durable Clinical Response to DC/AML Fusion Vaccine. <i>Blood</i> , 2019 , 134, 3832-3832	2.2	
55	Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies. <i>Blood</i> , 2019 , 134, 3227-3227	2.2	
54	KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. <i>Cell</i> , 2018 , 172, 857-868.e15	56.2	142
53	Amplification of Wild-type Imparts Resistance to Crizotinib in Exon 14 Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 5963-5976	12.9	42
52	Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche. <i>Leukemia</i> , 2018 , 32, 1739-1750	10.7	22
51	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. <i>Blood</i> , 2018 , 132, 749-749	2.2	6
50	Single-Cell RNA Sequencing Reveals Compromised Immune Microenvironment in Precursor Stages of Multiple Myeloma. <i>Blood</i> , 2018 , 132, 2603-2603	2.2	1
49	Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia. <i>PLoS ONE</i> , 2018 , 13, e0204589	3.7	13

48	Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. <i>Blood</i> , 2018 , 132, 2608-2612	2.2	19
47	Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 204-213	12.9	57
46	Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. <i>Cancer Research</i> , 2017 , 77, 2712-2721	10.1	81
45	The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. <i>Cell Reports</i> , 2017 , 19, 218-224	6.6	67
44	Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 3148-56	12.9	49
43	Driver Mutation in Waldenstrom's Macroglobulinemia and Their Clonal Heterogeneity during Progression and Relapse. <i>Blood</i> , 2016 , 128, 1092-1092	2.2	2
42	In Vivo Genome-Wide Crispr Library Screen in a Xenograft Mouse Model of Tumor Growth and Metastasis of Multiple Myeloma. <i>Blood</i> , 2016 , 128, 1137-1137	2.2	2
41	Whole-Exome Sequencing and Targeted Deep Sequencing of cfDNA Enables a Comprehensive Mutational Profiling of Multiple Myeloma. <i>Blood</i> , 2016 , 128, 197-197	2.2	7
40	Whole Exome Sequencing and Targeted Sequencing Reveal the Heterogeneity of Genomic Evolution and Mutational Profile in Smoldering Multiple Myeloma. <i>Blood</i> , 2016 , 128, 237-237	2.2	
39	Microrna-138 Regulates Osteogenic Differentiation and Its Inhibition Presents a Novel Therapeutic Line to Prevent Bone Lytic Lesions in Multiple Myeloma. <i>Blood</i> , 2016 , 128, 4483-4483	2.2	
38	Profiling of Circulating Exosomes in Patients with Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2016 , 128, 2940-2940	2.2	
37	A functional landscape of resistance to ALK inhibition in lung cancer. <i>Cancer Cell</i> , 2015 , 27, 397-408	24.3	123
36	Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. <i>Cancer Immunology Research</i> , 2015 , 3, 1333-1343	12.5	25
35	Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. <i>Cancer Research</i> , 2015 , 75, 4372-83	10.1	83
34	Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. <i>Cancer Research</i> , 2015 , 75, 3139-46	10.1	26
33	EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. <i>Clinical Cancer Research</i> , 2015 , 21, 3913-23	12.9	256
32	Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer. <i>Cancer Discovery</i> , 2015 , 5, 960-971	24.4	142
31	Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. <i>Clinical Cancer Research</i> , 2014 , 20, 6551-8	12.9	67

30	Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, E4869-77	11.5	125
29	Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. <i>Cancer Cell</i> , 2014 , 26, 909-922	24.3	294
28	Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. <i>Nature Medicine</i> , 2013 , 19, 1469-1475	17.5	420
27	Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 17041-6	11.5	170
26	Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. <i>Cancer Research</i> , 2013 , 73, 834-43	10.1	153
25	Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2173-81	2.2	214
24	Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. <i>Cancer Discovery</i> , 2012 , 2, 934-47	17.4	212
23	Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. <i>Cell</i> , 2012 , 150, 1107-20	50.0	1304
22	EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. <i>Clinical Cancer Research</i> , 2012 , 18, 1790-7	12.9	115
21	Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. <i>Nature Medicine</i> , 2012 , 18, 382-4	50.5	664
20	Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2063-9	2.2	197
19	A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 963-72	8.9	25
18	A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. <i>Cancer Research</i> , 2011 , 71, 6051-60	10.1	468
17	Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. <i>Oncogene</i> , 2010 , 29, 2346-56	9.2	185
16	Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. <i>British Journal of Cancer</i> , 2010 , 102, 1495-502	8.7	118
15	Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. <i>New England Journal of Medicine</i> , 2010 , 363, 1727-33	59.2	622
14	The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. <i>Cancer Research</i> , 2010 , 70, 10038-43	10.1	264
13	Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. <i>Cancer Research</i> , 2010 , 70, 9827-36	10.1	164

12	Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers. <i>Lung Cancer</i> , 2010 , 67, 355-60	5.9	59
11	Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. <i>Cancer Cell</i> , 2010 , 17, 77-88	24.3	816
10	Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. <i>Biochemical Pharmacology</i> , 2009 , 78, 460-8	6	61
9	Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. <i>Nature</i> , 2009 , 462, 1070-4	50.4	766
8	Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1789-96	2.2	784
7	Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2008 , 3, 1104-11	8.9	29
6	Refractory Pleural Small Cell Carcinoma in Never Smoker. A Case Report. <i>Tumori</i> , 2008 , 94, 434-436	1.7	1
5	BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study. <i>Breast</i> , 2007 , 16, 280-92	3.6	97
4	Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 6518-26	12.9	20
3	A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes. <i>Breast Cancer Research and Treatment</i> , 2005 , 91, 203-5	4.4	18
2	Molecular Profile and Clinical Variables in Brca1-Positive Breast Cancers. A Population-Based Study. <i>Tumori</i> , 2005 , 91, 505-512	1.7	11
1	Characterization of GSTM3 polymorphism by real-time polymerase chain reaction with LightCycler. <i>Analytical Biochemistry</i> , 2004 , 330, 175-7	3.1	3